Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment
- PMID: 30231410
- PMCID: PMC6415750
- DOI: 10.1200/EDBK_201391
Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment
Abstract
The growing population of cancer survivors often faces adverse effects of treatment, which have a substantial impact on morbidity and mortality. Although certain adverse effects are thought to have a significant heritable component, much work remains to be done to understand the role of germline genetic factors in the development of treatment-related toxicities. In this article, we review current understanding of genetic susceptibility to a range of adverse outcomes among cancer survivors (e.g., fibrosis, urinary and rectal toxicities, ototoxicity, chemotherapy-induced peripheral neuropathy, subsequent malignancies). Most previous research has been narrowly focused, investigating variation in candidate genes and pathways such as drug metabolism, DNA damage and repair, and inflammation. Few of the findings from these earlier candidate gene studies have been replicated in independent populations. Advances in understanding of the genome, improvements in technology, and reduction in laboratory costs have led to recent genome-wide studies, which agnostically interrogate common and/or rare variants across the entire genome. Larger cohorts of patients with homogeneous treatment exposures and systematic ascertainment of well-defined outcomes as well as replication in independent study populations are essential aspects of the study design and are increasingly leading to the discovery of variants associated with each of the adverse outcomes considered in this review. In the long-term, validated germline genetic associations hold tremendous promise for more precisely identifying patients at highest risk for developing adverse treatment effects, with implications for frontline therapy decision-making, personalization of long-term follow-up guidelines, and potential identification of targets for prevention or treatment of the toxicity.
Conflict of interest statement
Disclosures of potential conflicts of interest provided by the authors are available with the online article at
Figures
Similar articles
-
The influence of genetic variation on late toxicities in childhood cancer survivors: A review.Crit Rev Oncol Hematol. 2018 Jun;126:154-167. doi: 10.1016/j.critrevonc.2018.04.001. Epub 2018 Apr 12. Crit Rev Oncol Hematol. 2018. PMID: 29759558 Review.
-
Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2048-67. doi: 10.1158/1055-9965.EPI-11-0659. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21980013 Free PMC article. Review.
-
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.JAMA. 2017 Sep 5;318(9):825-835. doi: 10.1001/jama.2017.11137. JAMA. 2017. PMID: 28873162 Free PMC article.
-
Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality.Clin Cancer Res. 2017 Aug 1;23(15):4010-4019. doi: 10.1158/1078-0432.CCR-17-0429. Epub 2017 Apr 25. Clin Cancer Res. 2017. PMID: 28442506 Free PMC article. Review.
-
Chronic health conditions in childhood cancer survivors: is it all treatment-related--or do genetics play a role?J Gen Intern Med. 2009 Nov;24 Suppl 2(Suppl 2):S395-400. doi: 10.1007/s11606-009-0995-8. J Gen Intern Med. 2009. PMID: 19838838 Free PMC article. Review.
Cited by
-
Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors.Nat Med. 2024 Mar;30(3):690-698. doi: 10.1038/s41591-024-02837-7. Epub 2024 Mar 7. Nat Med. 2024. PMID: 38454124 Free PMC article.
-
Oncology Scan: Radiation Biology and Genomic Predictors of Response.Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):393-397. doi: 10.1016/j.ijrobp.2020.04.008. Int J Radiat Oncol Biol Phys. 2020. PMID: 32531379 Free PMC article. No abstract available.
-
Testicular Cancer as a Model for Understanding the Impact of Evolving Treatment Strategies on the Long-Term Health of Cancer Survivors.JNCI Cancer Spectr. 2020 Feb 27;4(3):pkaa013. doi: 10.1093/jncics/pkaa013. eCollection 2020 Jun. JNCI Cancer Spectr. 2020. PMID: 32455333 Free PMC article. No abstract available.
-
Risk of second primary cancers in individuals diagnosed with index smoking- and non-smoking- related cancers.J Cancer Res Clin Oncol. 2020 Jul;146(7):1765-1779. doi: 10.1007/s00432-020-03232-8. Epub 2020 Apr 30. J Cancer Res Clin Oncol. 2020. PMID: 32356175 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources